Adamo et al. reported the biological effect of oral metronomic vinorelbine alone or in combination with endocrine therapy in 61 post-menopausal women with untreated stage I–III HR + /HER2-negative breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.